Company Overview
Snapshot
Founded in December 1992 by Judith Richter and Kobi Richter, Medinol operates with 51–200 employees. The company focuses on cardiovascular intervention technologies, notably with its EluNIR drug-eluting stent. In September 2022, its subsidiary Microtech announced plans to unveil an implantable microsensor platform at the 34th Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, signaling continued innovation in medical device technology.
Business overview
Medinol is a medical device company dedicated to advancing cardiovascular intervention through the development, manufacturing, and marketing of innovative technologies. Its core product, EluNIR, is an elastomeric drug-eluting stent crafted from a thin cobalt-chrome alloy, designed for optimal flexibility, conformability, scaffolding, and a low metal footprint. This stent features the Flexx catheter technology, which enhances delivery ease in complex anatomies. Medinol serves the interventional cardiology market, providing solutions for patients with coronary artery narrowing or blockages, operating within the Health Tech & Life Sciences sector, specifically in Medical Devices and Drug Delivery.
Strategic signal
In September 2022, Medinol's subsidiary, Microtech, announced it would unveil its implantable microsensor platform at the 34th Transcatheter Cardiovascular Therapeutics (TCT) annual meeting. This development is significant as it introduces a new class of sensor technology capable of integrating with existing medical devices to enable data gathering, potentially expanding healthcare access and reducing the need for frequent office visits. This signals Medinol's strategic focus on integrating smart technology into its cardiovascular solutions, indicating a forward trajectory towards data-driven medical devices and enhanced patient monitoring capabilities.
Log in to access full profile ›Company Intelligence Q&A
- What significant technology did Medinol's subsidiary Microtech announce in September 2022?
- In September 2022, Medinol's subsidiary, Microtech, announced it would unveil its implantable microsensor platform at the 34th Transcatheter Cardiovascular Therapeutics (TCT) annual meeting. This platform is designed to integrate with existing medical devices, transforming them into smart, data-gathering tools for various medical conditions.
- What were the findings of the clinical study regarding Medinol's EluNIR stent in January 2020?
- In January 2020, a clinical study demonstrated that Medinol's EluNIR drug-eluting stent performed comparably to Medtronic's Resolute Integrity or Resolute Onyx stents. The study involved 2,221 participants, comparing Medinol's ridaforolimus-eluting stent with Medtronic's zotarolimus-eluting stent.
- When did Medinol's EluNIR drug-eluting stent first see commercial implants in the U.S.?
- In January 2018, Cordis, a Cardinal Health company, and Medinol announced the first commercial cases using the EluNIR drug-eluting stent in the United States. These initial implants were performed at New York-Presbyterian Hospital/Columbia University Medical Center and the Piedmont Heart Institute.
- When did Medinol receive FDA approval for its EluNIR drug-eluting stent?
- In December 2017, Medinol received FDA approval for its EluNIR drug-eluting stent. This approval was a significant milestone, marking the first for a privately held company based outside of the US for such a device.
- When did Medinol's EluNIR drug-eluting stent receive CE Mark approval in Europe?
- In October 2017, Medinol's EluNIR drug-eluting stent received CE Mark approval in Europe. This clearance allowed the device, designed to prevent restenosis with features like a flexible tip and minimal metal material, to be marketed across European countries.